Member Info for Bobbler

Nice 1m share buy,

RMM- can’t remember ever having a “50” likes tick. Well done sir!

Lack of Covid therapeutics is clearly a big issue.

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00333-3/fulltext

The need for treatments at all stages of covid-19 is more pronounced than ever given inequitable access to vaccines and surging cases across different parts of the world, including in Africa, Asia, and Latin America. It is further compounded by the possible waning of immunity over time, uncertainty around the efficacy of vaccines for immune-compromised individuals, vaccine hesitancy, and the continued impact of new variants of concern.

https://blogs.bmj.com/bmj/2021/08/06/will-science-deliver-needed-therapeutics-for-covid-19-and-how-can-equitable-access-be-ensured/

Boilb: some interesting statements in that article.

“We can’t be at all complacent about needing better therapies for patients with severe COVID.”

“Although COVID-19 vaccine development has been a huge success story, only two drugs have proved to reduce COVID-19 mortality in hospitalized patients.”

“United Kingdom’s Recovery trial found that dexamethasone, a cheap steroid, reduced deaths in that group by up to one-third.”

“Both drugs work by dampening the overshooting immune response in severely sick patients.”

Final sentence, would indicate our SDC-1801 is clearly in the space that’s proven to be the effective way forward.

MM's hover up them cheap shares and then sell them back after lunch for a tidy profit........why wouldn't they.

RM3383: I think you sparked an RNS with your last post mate! :-)

RMM - spot on

T2, certainly looks that way. Just a little more time for all to align.

Just browsing the register of interests for the SAGE advisors.

Professor Charlotte Deane:
Recipient of research funding, EPSRC, MRC, BBSRC, Rosetrees foundation, Roche, GSK, UCB, AstraZeneca, Boehringer Ingelheim, Exscientia, Kymab, BenevolentAI, Life Arc, Global Phasing.
Chair, UKRI COVID-19 Research and Innovation taskforce.

Research funding related to Kymab, Chair of UKRI Covid -19 Research and Innovation taskforce......

Sareum's Dr Michael Owen, co-founder and first CSO of Kymab Ltd
Sareum's covid funding grant provided by UKRI

Based on the study results coupled with the credibility of Sareum's management team, its hard to believe our Tyk2 isn't going to be progressed to the Agile trials.

https://www.reuters.com/world/asia-pacific/japans-covid-19-infections-have-entered-new-phase-says-health-minister-2021-08-04/

https://www.bbc.co.uk/news/health-58095503

Can we take time to remember……when the clowns gather it’s always a sign of better things to come.

You just have to remember, they’re here for a reason (and it’s not just because they’re sad, lonely and craving the attention mummy never gave them. Clinical proof that to much bottle feeding is a bad thing!)

They’re here because they know there is significant more upside to this share.

I find it hard not to respond to them, it’s actually good fun because they’re not bright enough to actually have an intellectual debate.

However, let’s not let them disrupt and turn what was a real good group into and argumentative shambles.

All’s good in the Sareum Hood.

Not sure if this has been mentioned before, pretty big market predicted sales of treatment by 2026 to reach USD 22.75 Billion. Cant imagine what a preventive would be worth.

Abstract from https://www.europarl.europa.eu/cmsdata/237593/IMI2_CAAR_2020.pdf

"Discovered potential T1D drug candidates. Two TYK2 inhibitors were tested and
shown dose dependant inhibition of the IFNa signalling in human beta cells, decreasing
its pro-inflammatory and pro-apoptotic effects without sensitising the cells to viral
infection. These preclinical findings could pave the way for future clinical trials with
TYK2 inhibitors for the prevention and treatment of type 1 diabetes."

https://pubmed.ncbi.nlm.nih.gov/32476252/

https://www.9news.com.au/national/federal-government-looking-to-secure-anti-covid-pills-that-could-reduce-the-effects-of-virus/38ac6286-6afa-4f3b-94fe-fe3da9a8e13c

Thoth2, indeed you have mentioned that, along with the young being more susceptible to the disease…..it’s a little concerning how accurate your predictions have been!

If you plan to float your “crystal ball” company in the future let me know, I would like to be an early investor!

Cheers for everything to date, it’s been life changing already, and would appear to have a lot more yet.

I wonder if we will have another RNS ref HNWI investment, 11-1130am has been the preferred time for those.

Not sure Trimme if you understand much at all.

"These patents are important to enhancing the value of the programme as part of our discussions with potential partners."

Personalized health and the coronavirus vaccines—Do individual genetics matter?

https://onlinelibrary.wiley.com/doi/10.1002/bies.202100087

Tyk2 mentioned.:
Different genetic factors or risk loci, mostly related to key host antiviral defense mechanisms and mediators of inflammation, have been reported since the beginning of the pandemic.[29, 30] Among them, a gene cluster on chromosome 3 inherited from Neanderthals has been identified as a potential predictor a COVID-19 severity.[31] Likewise, some novel GWAS significant hits on chr12q24.13 (rs10735079, p = 1.6 × 10–8) in a gene cluster encoding antiviral restriction enzyme activators (OAS1-3); on chr19p13.2-3 (rs2109069, p = 2.3 × 10–12 and rs2109069, p = 3.9 × 10–12) near the gene encoding tyrosine kinase 2 (TYK2) and within the gene encoding dipeptidyl peptidase 9 (DPP9)